Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M510997200 on April 27, 2006

J. Biol. Chem., Vol. 281, Issue 29, 20148-20159, July 21, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/29/20148    most recent
M510997200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitau, J.
Right arrow Articles by Charreau, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitau, J.
Right arrow Articles by Charreau, B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Adaptor Molecule Lnk Negatively Regulates Tumor Necrosis Factor-{alpha}-dependent VCAM-1 Expression in Endothelial Cells through Inhibition of the ERK1 and -2 Pathways*

Juliette Fitau1, Gwénola Boulday2, Flora Coulon, Thibaut Quillard, and Béatrice Charreau3

From the INSERM, U643, Nantes, France, Institut de Transplantation et de Recherche en Transplantation, Centre Hospitalier Universitaire, and Université de Nantes, Unité de Formation et de Recherche de Médecine, F-44093 Nantes, France

Lnk, with APS and SH2-B (Src homology 2-B), belongs to a family of SH2-containing proteins with potential adaptor functions. Lnk regulates growth factor and cytokine receptor-mediated pathways implicated in lymphoid, myeloid, and platelet homeostasis. We have previously shown that Lnk is expressed and up-regulated in vascular endothelial cells (ECs) in response to tumor necrosis factor-{alpha} (TNF{alpha}). In this study, we have shown that, in ECs, Lnk down-regulates the expression, at both mRNA and protein levels, of the proinflammatory molecules VCAM-1 and E-selectin induced by TNF{alpha}. Mechanistically, our data indicated that, in response to TNF{alpha}, NF{kappa}B/p65 phosphorylation and translocation as well as I{kappa}B{alpha} phosphorylation and degradation were unchanged, suggesting that Lnk does not modulate NF{kappa}B activity. However, Lnk activates phosphatidylinositol 3-kinase (PI3K) as reflected by Akt phosphorylation. Our results identify endothelial nitric-oxide synthase as a downstream target of Lnk-mediated activation of the PI3K/Akt pathway and HO-1 as a new substrate of Akt. We found that sustained Lnk-mediated activation of PI3K in TNF{alpha}-activated ECs correlated with the inhibition of ERK1/2 phosphorylation, whereas phosphorylation of p38 and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) was unchanged. ERK1/2 inhibition decreases VCAM-1 expression in TNF{alpha}-treated ECs. Collectively, our results identify the adaptor Lnk as a negative regulator in the TNF{alpha}-signaling pathway mediating ERK inhibition and suggest a role for Lnk in the interplay between PI3K and ERK triggered by TNF{alpha} in ECs.


Received for publication, October 7, 2005 , and in revised form, April 20, 2006.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by fellowships from La Société Francophone de Transplantation, La Société deNéphrologie and La Fondation ProGreffe.

2 Supported by a fellowship from the Fondation pour la Recherche Médicale. Present address: Children's Hospital, Division of Nephrology, Boston, MA 02115.

3 To whom correspondence should be addressed: INSERM U643, ITERT, CHU Hôtel-Dieu, 30 Bd Jean Monnet, F-44093 Nantes, France. Tel.: 33-240-087-416; Fax: 33-240-087-411; E-mail: Beatrice.Charreau{at}univ-nantes.fr.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
J. Ashton-Chess, M. Giral, M. Mengel, K. Renaudin, Y. Foucher, W. Gwinner, C. Braud, E. Dugast, T. Quillard, P. Thebault, et al.
Tribbles-1 as a Novel Biomarker of Chronic Antibody-Mediated Rejection
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1116 - 1127.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement